United States securities and exchange commission logo





                             June 15, 2021

       Markus Warmuth
       President and Chief Executive Officer
       Monte Rosa Therapeutics, Inc.
       645 Summer Street, Suite 102
       Boston, MA 02210

                                                        Re: Monte Rosa
Therapeutics, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed June 9, 2021
                                                            File No. 333-256773

       Dear Dr. Warmuth:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment 1 to Form S-1 Filed on June 9, 2021

       Dilution, page 85

   1.                                                   Please revise your
calculations for your net tangible and pro forma net tangible book value
                                                        (deficit) per share as
of March 31, 2021 to utilize 6,079,905 outstanding underlying the
                                                        calculation disclosed
on pages F-30 and F-32 as of March 31, 2021 rather than 7,699,359
                                                        shares outstanding,
which are a result of the unvested shares of restricted stock being
                                                        classified as issued
but not outstanding.
 Markus Warmuth
FirstName
Monte RosaLastNameMarkus
            Therapeutics, Inc.Warmuth
Comapany
June       NameMonte Rosa Therapeutics, Inc.
     15, 2021
June 15,
Page 2 2021 Page 2
FirstName LastName
       You may contact Tara Harkins at 202-551-3639 or Lynn Dicker at
202-551-3616 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Kasey Robinson at 202-551-5880 or Jeffrey Gabor at 202-551-2544 with
any other
questions.



                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences
cc:      Robert E. Puopolo, Esq.